MedTrace Logo

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

NCT00154076 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2009-09-02

No results posted yet for this study

Summary

To assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Conditions

Interventions

DRUG

Zonisamide

Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.

DRUG

Topiramate

Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Principal Investigators

  • Jihee Mun · Eisai Korea Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-08-31
Completion
2008-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154076 on ClinicalTrials.gov